<strong>Objective:</strong> To preliminary study the significance of low molecular weight heparin (LMWH) in the treatment patients of with anemia of chronic diseases (ACD), and the changes in the serum lev...<strong>Objective:</strong> To preliminary study the significance of low molecular weight heparin (LMWH) in the treatment patients of with anemia of chronic diseases (ACD), and the changes in the serum levels of BMP6, hepcidin and IL-6. To preliminary study the significance of low molecular weight heparin (LMWH) in the treatment the patients with anemia of chronic diseases (ACD), and the changes in the serum levels of BMP6, hepcidin and IL-6. <strong>Methods:</strong> Used LMWH (4000 u/day, 7 - 15 days) to therapy 61 patients with ACD, and ELISA method was used to determine Hepcidin and BMP6 before and after treatment, and the determination of IL-6 by Electro-chemi-luminescence, and to analyze its clinical significance. <strong>Results:</strong> 1) In all 61 cases, the levels of Hepcidin in post-therapy were 0.82 ± 0.24 mg/L, which were lower than 1.05 ± 3.83 mg/L in pre-therapy (t = 2.5726, <em>P</em> < 0.05). The levels of IL-6 in post-therapy were 24.88 ± 12.58 mg/L, which were lower than 38.22 ± 31.23 mg/L in pre-therapy (t = 2.9650, <em>P</em> < 0.05), but there were no statistically significant both Hb and BMP6 between in pre-therapy and post-therapy (all <em>P</em> > 0.05). However, The levels of Hb in post-therapy were higher than in pre-therapy (t = 1.9832, <em>P</em> < 0.05). 2) The Hb level in the tumor anemia group after treatment was 91.18 ± 15.91 g/L, which was higher than that before treatment (85.45 ± 18.33 g/L), the difference was statistically significant (t = 1.9711, <em>P</em> < 0.05). 3) The levels of hepcidin and IL-6 in the tumor anemia group after treatment were 0.73 ± 0.45 mg/L and 30.33 ± 28.39 mg/ml, which were lower than those before treatment (1.09 ± 0.41 mg/L and 50.76 ± 42.10 mg/ml), respectively, the difference was statistically significant (t = 3.3941, <em>P </em>< 0.01 and t = 2.3597, <em>P</em> < 0.05). 4) There was no significant difference in all indexes in tumor anemia free group (all <em>P</em> > 0.05). 5) Although Hb level increased slightly in the non-tumor anemia group, there was no statistical significance (<em>P</em> > 0.05), and there was no statistical difference in other indexes (all <em>P</em> > 0.05). 6) After treatment, the level of Hb was negatively correlated with Hepcidin and IL-6 (respectively r = -0.2809, t = 2.2490, <em>P</em> < 0.05 and r = -0.2781, t = 2.2266, <em>P</em> < 0.05). Hepcidin was positively related to IL-6 (r = -0.2941, t = 2.3622, <em>P</em> < 0.05). There was no correlation between BMP6 and Hb, Hepcidin and IL-6 levels. <strong>Conclusion:</strong> LMWH could up-regulate the levels of Hb, and better for the degree of anemia in patients with ACD. The possible mechanism is to reduce the level of Hepcidin and IL-6.展开更多
文摘<strong>Objective:</strong> To preliminary study the significance of low molecular weight heparin (LMWH) in the treatment patients of with anemia of chronic diseases (ACD), and the changes in the serum levels of BMP6, hepcidin and IL-6. To preliminary study the significance of low molecular weight heparin (LMWH) in the treatment the patients with anemia of chronic diseases (ACD), and the changes in the serum levels of BMP6, hepcidin and IL-6. <strong>Methods:</strong> Used LMWH (4000 u/day, 7 - 15 days) to therapy 61 patients with ACD, and ELISA method was used to determine Hepcidin and BMP6 before and after treatment, and the determination of IL-6 by Electro-chemi-luminescence, and to analyze its clinical significance. <strong>Results:</strong> 1) In all 61 cases, the levels of Hepcidin in post-therapy were 0.82 ± 0.24 mg/L, which were lower than 1.05 ± 3.83 mg/L in pre-therapy (t = 2.5726, <em>P</em> < 0.05). The levels of IL-6 in post-therapy were 24.88 ± 12.58 mg/L, which were lower than 38.22 ± 31.23 mg/L in pre-therapy (t = 2.9650, <em>P</em> < 0.05), but there were no statistically significant both Hb and BMP6 between in pre-therapy and post-therapy (all <em>P</em> > 0.05). However, The levels of Hb in post-therapy were higher than in pre-therapy (t = 1.9832, <em>P</em> < 0.05). 2) The Hb level in the tumor anemia group after treatment was 91.18 ± 15.91 g/L, which was higher than that before treatment (85.45 ± 18.33 g/L), the difference was statistically significant (t = 1.9711, <em>P</em> < 0.05). 3) The levels of hepcidin and IL-6 in the tumor anemia group after treatment were 0.73 ± 0.45 mg/L and 30.33 ± 28.39 mg/ml, which were lower than those before treatment (1.09 ± 0.41 mg/L and 50.76 ± 42.10 mg/ml), respectively, the difference was statistically significant (t = 3.3941, <em>P </em>< 0.01 and t = 2.3597, <em>P</em> < 0.05). 4) There was no significant difference in all indexes in tumor anemia free group (all <em>P</em> > 0.05). 5) Although Hb level increased slightly in the non-tumor anemia group, there was no statistical significance (<em>P</em> > 0.05), and there was no statistical difference in other indexes (all <em>P</em> > 0.05). 6) After treatment, the level of Hb was negatively correlated with Hepcidin and IL-6 (respectively r = -0.2809, t = 2.2490, <em>P</em> < 0.05 and r = -0.2781, t = 2.2266, <em>P</em> < 0.05). Hepcidin was positively related to IL-6 (r = -0.2941, t = 2.3622, <em>P</em> < 0.05). There was no correlation between BMP6 and Hb, Hepcidin and IL-6 levels. <strong>Conclusion:</strong> LMWH could up-regulate the levels of Hb, and better for the degree of anemia in patients with ACD. The possible mechanism is to reduce the level of Hepcidin and IL-6.
